Takeda is beefing up its NASH pipeline with a $470M discovery deal with HemoShear
Ten months after tying up with Arcturus on an RNA program for NASH, Takeda is back beefing up its pipeline for the liver disease by turning to the Charlottesville, VA biotech.
NASH is one of the liver diseases Takeda and HemoShear plan to suss out in a $470 million discovery collaboration, which includes an upfront and R&D money as well as a long string of milestones for any longterm successes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.